Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Ovarian tumours.

Drugs Under Experimental and Clinical Research

|January 1, 1986

Summary

This summary is machine-generated.

A novel "changing scheme" chemotherapy regimen demonstrated superior efficacy and reduced toxicity in advanced ovarian cancer patients compared to standard treatments. This regimen offers improved remission rates, duration, and survival, representing a significant advancement in ovarian cancer treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[Statement of the Austrian Society of Pneumology (ASP)].

Wiener klinisches Magazin : Beilage zur Wiener klinischen Wochenschrift·2020

Same author

Interobserver agreement and accuracy of non-invasive diagnosis of endometriosis by transvaginal sonography.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2015

Same author

Dyspareunia and quality of sex life after surgical excision of endometriosis: a systematic review.

European journal of obstetrics, gynecology, and reproductive biology·2013

Same author

Which lumen is the source of catheter-related bloodstream infection in patients with multi-lumen central venous catheters?

Infection·2013

Same author

Diagnostic delay for endometriosis in Austria and Germany: causes and possible consequences.

Human reproduction (Oxford, England)·2012

Same author

Toxoplasmic encephalitis.

Diseases of the nervous system·2010

Same journal

A comparison of the effects of D-003 and policosanol (5 and 10 mg/day) in patients with type II hypercholesterolemia: a randomized, double-blinded study.

Drugs under experimental and clinical research·2006

Same journal

Psychiatric factors in patients with sensitive skin.

Drugs under experimental and clinical research·2006

Same journal

Objective biophysical findings in patients with sensitive skin.

Drugs under experimental and clinical research·2006

Same journal

Is itraconazole the treatment of choice in Microsporum canis tinea capitis?

Drugs under experimental and clinical research·2006

Same journal

Improvement of otitis media with effusion after treatment of asthma with leukotriene antagonists in children with co-existing disease.

Drugs under experimental and clinical research·2006

Same journal

Twice-daily dosing of loracarbef 15 mg/kg versus 30 mg/kg in the treatment of children with acute sinusitis.

Drugs under experimental and clinical research·2006

See all related articles

Area of Science:

Oncology
Clinical Trials
Chemotherapy

Background:

Advanced ovarian cancer presents a poor prognosis with challenges in comparing chemotherapy outcomes due to numerous prognostic factors.
Existing treatment protocols for ovarian cancer often yield contradictory results, necessitating standardized research approaches.

Purpose of the Study:

To evaluate the efficacy and toxicity of a novel "changing scheme" chemotherapy regimen against standard treatments in advanced ovarian cancer.
To compare different chemotherapy regimens, including adriamycin/cyclophosphamide and adriamycin/cis-platin, with a multi-drug "changing scheme" in a randomized trial.

Main Methods:

A randomized trial involving 300 patients with advanced ovarian cancer, with 160 patients in stage III and IV.
Three treatment arms were compared: adriamycin/cyclophosphamide (A/C), adriamycin/cis-platin (A/P), and a "changing scheme" (A/P-V/C-HD-MTX).

Related Experiment Videos

Patient data was balanced using a computer process considering relevant prognostic factors.

Main Results:

The "changing scheme" demonstrated a significant advantage in remission rate, duration, and survival time compared to A/C and A/P.
This superiority was particularly noted in patients with G1 tumors, without ascites, with liver metastases, and a large postoperative tumor burden.
The "changing scheme" exhibited less toxicity than the adriamycin/cis-platin regimen.

Conclusions:

The "changing scheme" chemotherapy regimen represents a significant improvement for advanced ovarian cancer treatment, offering better outcomes and reduced toxicity.
This approach may contribute to improved survival and quality of life for ovarian cancer patients.
Further research and clinical application of this multi-drug changing scheme are warranted.